Bloomberg Businessweek cover image

Bristol’s $14 Billion Karuna Deal Highlights Race for New Drugs

Bloomberg Businessweek

00:00

Bristol Myers Squibb's $14 Billion Acquisition of Karuna Therapeutics

This chapter discusses the news of Bristol Myers Squibb acquiring Karuna Therapeutics for $14 billion, highlighting the race among drug makers to expand their portfolio. It explores the implications of the deal, the competitive process involved, and potential areas of interest for drug makers. The chapter also discusses the prospects of M&A activity in the biotech sector and the broader market going forward.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app